• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » ESC adds St. Jude’s CardioMems to guidelines for directed HF therapy

ESC adds St. Jude’s CardioMems to guidelines for directed HF therapy

June 6, 2016 By Fink Densford

St. Jude Medical's CardioMEMS implantable heart monitorThe European Society of Cardiology has added St. Jude Medical‘s (NYSE:STJ) CardioMems heart failure system to its guidelines as a “directed therapy management and monitoring tool for heart failure patients,” the company said today.

The CardioMems device consists of a wireless sensor implanted in the pulmonary artery via catheter to directly measure pressure in the vessel. The device is designed to help physicians manage patients’ medication to control their heart failure before visible changes to weight or blood pressure occur.

The new guidelines, published this year, support the use of pulmonary artery pressure monitoring with the CardioMems HF system for the diagnosis and treatment of acute and chronic heart failure, St. Jude said.

“The ESC guideline for the CardioMEMS HF System provides direction for physicians who are working to appropriately treat our heart failure patients and reduce their risk of repeated heart failure hospitalizations,” Dr. Giovanni Perego of Milan, Italy’s Istituto Auxologico Italiano said in a press release.

The company said data from the Champion study of the device served as a base for the updated guideline, which the company says applies to all Class II heart failure patients, regardless of their ejection fraction.

“We are very pleased to see the CardioMEMS HF System was included in the guidelines and congratulate the European Society of Cardiology for working to make this technology more widely available to benefit patients living with heart failure,” medical affairs veep Dr. Philip Adamson

The addition is a big win for St. Jude, after a Medicare contractor in February said it would not cover the CardioMEMS implantable heart monitor, citing the need for more clinical data on the device.

Novitas, a Medicare Administrative Contractor that covers patients in Pennsylvania, New Jersey, Maryland, Delaware, Colorado, Oklahoma, New Mexico, Texas, Arkansas, Louisiana, Mississippi and and Washington, D.C., said it would not cover the CardioMEMS device, which is designed to monitor patients for signs of heart failure.

In November 2015, St. Jude put another brick in the wall of its defense of the CardioMEMS device, touting data from the Champion trial showing lower hospitalization rates for patients treating using data from the CardioMEMS device.

In September 2015, a study from the non-profit Institute for Clinical and Economic Review in Boston found that the CardioMEMS device may not be a cost-effective solution for patients with congestive heart failure, saying it’s priced about $10,000 higher than ICER’s “value-based price benchmark” of $7,622.

Filed Under: Cardiac Implants, Cardiovascular Tagged With: stjudemedical

More recent news

  • Real-world data backs Route 92 reperfusion system
  • LivsMed unveils new surgical robot with telesurgery capabilities
  • JenaValve enrolls first patient in TAVR for AR study
  • HistoSonics expands insurance coverage for histotripsy treatment
  • Johnson & Johnson MedTech gets updated FDA nod for Varipulse PFA

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy